Alexion Pharmaceuticals Inc
AstraZeneca to Acquire Alexion for $39 Billion, Stock Down
A Look at Sarepta Therapeutics’ Stock Performance
After its stellar rise from $54.02 on January 8 to a high of $161.51 on September 28, Sarepta stock has seen selling pressure amid the market volatility in October.
Backing Out of the Synageva BioPharma Deal, Part 3
Things like acts of war and natural disasters aren’t MACS unless they disproportionately affect Synageva relative to other early-clinical-stage biopharmaceutical companies.
Alexion Pharmaceuticals Adds Metabolic Drug Kanuma to Portfolio
Kanuma was acquired by Alexion Pharmaceuticals on completion of the acquisition of Synageva Pharmaceuticals in June 2015.
What to Expect from BioMarin Pharmaceuticals in 2017
In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).
How BioMarin Pharmaceutical Is Positioned Financially in August
In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.
Wilson Disease: A Market Opportunity for Alexion
Wilson Therapeutics is developing a drug to treat Wilson disease. Wilson disease is a rare genetic disorder that’s potentially life-threatening.
A Look at Incyte’s Valuation as of May 25
Incyte reported EPS of -$0.19 on revenue of $382.3 million in Q1 2018 compared to revenue of $384.1 million in Q1 2017.
Inside Alexion’s Metabolic Drugs Kanuma and Strensiq
In 1Q16, Strensiq added $33.2 million to Alexion Pharmaceuticals’ top line. Now the drug is in its initial launch phase in the US, Germany, and Japan.
Alexion Continues to Rise on FDA’s Approval of Kanuma
Alexion Pharmaceuticals (ALXN) gained 2.5% on December 10, 2015. The stock went up after the FDA (Food and Drug Administration) approved its drug, Kanuma.
WTX101: A Superior Treatment for Wilson Disease
WTX101 has a unique action mechanism. The drug has the potential to become the standard of care for Wilson disease patients.
Revenue Drivers for Krystexxa, Horizon’s Orphan Biologic Drug
Horizon plans to drive Krystexxa through increased awareness and outreach, investing in its marketing and medical education as well as commercial infrastructure.
BioMarin’s Disappointing 3Q16 Earnings
BioMarin Pharmaceutical (BMRN) reported its 3Q16 earnings on October 27, 2016. Revenues were $279.9 million, which was lower than Wall Street analysts’ projections.
How Kanuma’s Addition to Alexion’s Portfolio Impacts Its Earnings
Alexion added Kanuma to its portfolio in 2015 after its Synageva acquisition. But ALXN didn’t have much time to build diagnostics as it did with Strensiq.
BioMarin Leads in the Market for Mucopolysaccharidoses Disorders
BioMarin holds three drugs in its portfolio indicated for different types of mucopolysaccharidoses disorders. They are Vimizim, Naglazyme, and Aldurazyme.
How Alexion Plans to Fuel Strensiq Sales
With the Enobia acquisition in February 2012, Alexion benefited in long-term disease awareness, diagnostic planning, and initiatives in the HPP space.
Why Are Most Analysts Recommending a ‘Buy’ for Vertex?
On February 16, 2016, after Vertex’s (VRTX) 4Q15 and fiscal 2015 earnings release, revised ratings showed that 76% of analysts now recommend a “buy” for Vertex stock.
Why Is Vertex Pharmaceuticals’ Valuation at a Discount?
On February 17, 2016, Vertex Pharmaceuticals (VRTX) was trading at a forward PE multiple of 15.20x. It’s trading at a discount when compared to peers Alexion (ALXN) and Regeneron (REGN).
Bridgewater: What Are Ray Dalio’s Top Investing Ideas?
Founded by Ray Dalio, Bridgewater Associates’ top sell in the third quarter was the iShares MSCI Emerging Markets ETF (EEM).
How BioMarin Pharmaceutical’s Financials Look in November
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year.
How Analysts View Alexion Stock
In November 2018, of the total 18 analysts covering Alexion Pharmaceuticals (ALXN), 16 analysts have given the stock a “buy” or higher rating, and two analysts have given it a “hold” rating.
Analyzing Alexion Pharmaceuticals’ Product Performance
Alexion Pharmaceuticals’ (ALXN) key products on the market include Soliris, Strensiq, and Kanuma.
Analyzing Sarepta’s Product Pipeline
Sarepta is expected to incur R&D expenses of $277.8 million in fiscal 2018, compared with $166.71 million in fiscal 2017.
How Alexion Pharmaceuticals Is Positioned in October
In September, Alexion Pharmaceuticals agreed to acquire Syntimmune, a clinical stage biotechnology company.
Ionis Pharmaceuticals’ Revenue Growth Rate
Ionis Pharmaceuticals (IONS) reported revenues of $262.0 million during the first half of 2018.
How Analysts View BioMarin Pharmaceutical in August
On August 30, 2018, BioMarin Pharmaceutical (BMRN) stock closed at $99.26 which is 7% below its 52-week high of $106.20 on August 2.
What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?
In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.
Analysts Are Bullish on Sarepta Therapeutics
Sarepta Therapeutics (SRPT) reported revenues of $64.6 million and a net loss of $0.55 per share in Q1 2018.
How Does BioMarin Pharmaceutical Look ahead of Its Q2 Earnings?
BioMarin Pharmaceutical (BMRN) plans to release its Q2 2018 results on August 2. In Q1 2018, BMRN reported net revenues of $373.4 million.
Alexion Pharmaceuticals in 4Q17 and Fiscal 2017
In 4Q17, Alexion Pharmaceuticals (ALXN) generated revenues of $910 million, which reflected ~10% growth on a YoY (year-over-year) basis.
Inside Pfizer’s Rare Disease Segment Performance in 2017
In 4Q17, Pfizer’s BeneFix reported revenues of $150 million, which represents a ~11% decline YoY and a ~1% decline quarter-over-quarter.
How Biogen’s Spinraza Is Positioned for 2018
In 4Q17, Biogen’s (BIIB) Spinraza generated revenues of $363 million, which reflected 34% quarter-over-quarter growth.
A Look at Ionis Pharmaceuticals’ January 2018 Valuation
On January 5, Ionis Pharmaceuticals’ stock value had risen ~4.3% over the last 12 months. Analysts expect the stock to rise ~14.0% over the next 12 months.
How’s Incyte’s Valuation in January 2018?
Analysts expect Incyte Corporation’s revenue to rise ~26.7% to $413.8 million in 4Q17 compared to $326.5 million in 4Q16.
Thermo Fisher Scientific’s Deepening Ties with Sema4
Thermo Fisher Scientific’s (TMO) Core Informatics’ Platform for Science’s modules, including a LIMS (laboratory information management system), could soon be implemented at Sema4’s two major laboratory facilities.
Givosiran May Become Major Growth Driver for Alnylam Pharmaceuticals
On September 7, 2017, Alnylam Pharmaceuticals (ALNY) announced that it had reached an agreement with the US Food and Drug Administration (or FDA) related to the design of the phase three program for investigational RNAi therapeutic Givosiran.
Patisiran Expected to Become Key Growth Driver for Alnylam
Alnylam Pharmaceuticals’ (ALNY) investigational drug Patisiran is expected to target 20,000 to 30,000 patients with hereditary ATTR (or hATTR) Amyloidosis with polyneuropathy caused by amyloid deposition in nerves.
How Is Jazz’s Defitelio Positioned after 2Q17?
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.
This Part of Bioverativ’s Pipeline Could Be a Major Long-Term Growth Driver
In June 2017, the FDA accepted Bioverativ’s investigative new drug application for BIVV001, a drug designed to treat prophylaxis from bleeding associated with hemophilia A.
Behind Bioverativ’s Analyst Recommendations This September
Of the 12 analysts tracking Bioverativ (BIVV), three recommend a “strong buy” for the stock, while one recommends a “buy,” and seven recommend a “hold.”
How Are Orkambi and Kalydeco Positioned after 2Q17?
In 2Q17, Vertex Pharmaceuticals’ (VRTX) Orkambi generated revenues of around $324 million, which reflected a whopping ~32% growth on a year-over-year (or YoY) basis and ~10% growth on a quarter-over-quarter basis.
Alprolix and Eloctate Increasingly Used for Prophylaxis in 2017
Since demand from the target population for prophylaxis is rising rapidly, Bioverativ’s Alprolix and Eloctate are expected to see solid demand trends in 2017.
Bioverativ Expected to Report Healthy Profit Margins in 2017
Bioverativ (BIVV) expects its 2017 GAAP and non-GAAP operating margins to fall 38.0%–42.0% and 43.0%–47.0%, respectively.
Bioverativ Expected to Report Robust Revenue Growth in 2017
In 1Q17, Bioverativ reported revenues close to $259.0 million, driven by its focus on a commercial strategy for its hemophilia products and optimal cost management.
Bioverativ–True North Therapeutics: Stronger Research Pipeline
The acquisition of True North Therapeutics has paved the way for Bioverativ’s (BIVV) entry into cold agglutinin disease (or CAD).
Vertex Pharmaceuticals Cystic Fibrosis Market Could Expand
Vertex Pharmaceuticals’ (VRTX) drugs, Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor), are capable of treating around 30,000 cystic fibrosis (or CF) patients.
What Analysts Recommend for BioMarin Pharmaceuticals
A total of 20 analysts were analyzing BioMarin Pharmaceuticals in July 2017. Six analysts recommended a “strong buy,” while nine analysts suggested a “buy.”
BioMarin Expects These Drugs to Generate Steady Revenues
In 2016, BioMarin Pharmaceuticals’ (BMRN) Naglazyme generated revenues of around $297 million, a ~2% year-over-year (or YoY) decline.
How Incyte’s Valuation Has Changed since 1Q17 Results
Incyte reported revenues of $384.1 million in 1Q17 as compared to $263.5 million in 1Q16.
Strensiq: Key Growth Driver for Alexion Pharmaceuticals in 2017
In 1Q17, Alexion Pharmaceuticals’ (ALXN) Strensiq generated revenue of ~$74 million, which reflects ~4% quarter-over-quarter and ~124% YoY growth.
ALXN1210 Is Expected to Boost Alexion Pharmaceuticals’ Revenue
Alexion Pharmaceuticals has planned five clinical trials in 2017 to test the potential of investigational next-generation C5 antibody, ALXN1210, as a treatment option for complement-mediated diseases.
Biogen’s Targeted Marketing Strategy for Spinraza in 1Q17
To promote the use of Spinraza for SMA, Biogen (BIIB) has been actively educating and creating awareness for the drug among physician and patient communities.
Valeant’s Net Profit Margins Expected to Narrow in 2017
Net profit margins Valeant Pharmaceuticals (VRX) has projected its adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) to fall $3.6 billion–$3.7 billion. Besides lower revenue, the company will also have to bear $1.9 billion in cash interest in 2017, which includes $100 million in amortized deferred financing costs. Wall Street analysts have projected that […]
Alnylam Pharmaceuticals’s Therapies to Treat hATTR Amyloidosis
The European Medicines Agency (or EMA) has approved tafamidis for stage 1 hATTR amyloidosis.
Vertex Has Adopted Multiple Approaches to Treat Cystic Fibrosis
Vertex Pharmaceuticals (VRTX) is aiming to increase the number of patients eligible to be treated with its drugs to include the entire CF patient population.
Why United Therapeutics Expects Strong Revenue Growth
United Therapeutics (UTHR) expects to earn revenue exceeding $1.5 billion in 2016. By 2020, the company also expects to surpass its goal of $2 billion in annual revenue.
What Are Analysts Saying about Horizon Pharma?
According to a Thomson Reuters Eikon consensus of six brokerage firms on December 17, 2016, 83.3% of the firms rated Horizon Pharma (HZNP) a “buy.”
Horizon Pharma’s Steep Fall in December: What Happened?
On December 8, 2016, Horizon Pharma (HZNP) announced that its Phase 3 STEADFAST trial for Actimmune didn’t meet its primary endpoint. Horizon stock fell 22.5% that day.
How Could Gilead Sciences Restore Its Growth?
With its continuous revenue fall, Gilead Sciences (GILD) could opt to restore its growth through acquisitions.
Why Europe Is an Important Market for Vertex’s Orkambi
Although there are 12,000 eligible patients in Europe who are 12 years and older, Orkambi hasn’t yet received reimbursement approvals for these patients.
Higher Discontinuations Are among Orkambi’s Concerns
Despite a slower launch of the drug in Germany, Orkambi is expected to generate $1 billion–$1.1 billion in 2016.
How Gilead Dominates the HCV Space
In January 2012, Gilead Sciences (GILD) acquired Pharmasset and got access to sofosbuvir. In December 2013, the FDA approved sofosbuvir under the brand name Sovaldi.
Will Teva Pharmaceutical Strengthen Specialty Pipeline in 3Q16?
Teva Pharmaceutical (TEVA) has been actively involved in multiple research programs in its specialty pipeline, including MS, movement disorders, and neurodegeneration, pain, and respiratory.
How Significant Is Alexion’s Opportunity with Soliris?
Alexion (ALXN) has been serving the atypical hemolytic uremic syndrome, or aHUS, market for the past five years.
Behind Alexion’s Updated Guidance for Its Metabolic Franchise
During the second quarter of 2016, Alexion (ALXN) witnessed 23% volume growth, resulting in an 18% annual revenue growth.
Alexion’s 2Q16 Earnings Just Might Impress You
Alexion Pharmaceuticals released its earnings for 2Q16 on July 28, reporting revenues of $753.1 million, which surpassed Wall Street analyst estimates.
The Word on the Street: How Analysts See BioMarin Now
According to Bloomberg, among 20 analysts, 90% recommend BioMarin as a “buy,” and the remaining 10% of analysts have issued a “hold” rating for the company.
Why Did Alexion Fall after Brexit?
Following Brexit, global equity markets experienced a crash. Anticipations of weaker European and British economies are likely reasons for the fall.
Effects of Brexit on Pharmaceuticals and the Biotechnology Industry
Global big pharmaceutical companies that have major exposure to Europe will be impacted significantly by Brexit. The depreciating euro will impact sales.
BioMarin Withdraws Application for Kyndrisa: Stock Falls 2.5%
As of June 1, 2016, BioMarin Pharmaceutical (BMRN) was the most underperforming stock among the large-cap stocks of the SPDR S&P Biotech ETF (XBI).
How Does Shire Lead the Angioedema Space?
Cinryze and Firazyr are Shire’s (SHPG) two drugs in its hereditary angioedema portfolio. Together, these two drugs crossed $1 billion in sales in fiscal 2015.
Why Has Teva Pharmaceutical Targeted Orphan Diseases?
Similar to Alexion’s Soliris, Amgen’s blinatumomab, and Celgene’s GED-301, SD-809 has received an ODD (orphan drug designation) from the FDA.
How Vyvanse Could Fuel Shire’s ADHD Portfolio Sales
Vyvanse is Shire’s leading ADHD drug, constituting 80% of the company’s ADHD portfolio. In fiscal 2015, Vyvanse earned the company $1.7 billion.
Analysts Are Optimistic About Shire
According to a Bloomberg consensus of 15 brokerage firms, 86.7% of analysts rated Shire a “buy,” and 13.3% rated it a “hold.” None issued a “sell” rating for the stock.
Shire at Discount on Price-to-Earnings Basis: A Good Opportunity?
With estimated double-digit sales growth and post-Baxalta-acquisition synergies, Shire’s PE could rise in the near term and result in a rise in share price.
Shire’s Acquisition Gives It Natpara and Gattex
Gattex is the first and only analog of glucagon-like peptide-2 (or GLP-2) indicated for short bowel syndrome. The drug is known as Gattex in the United States and Revestive in Europe.
Which Large-Cap Biotech Stock Fell the Most Last Week?
Large-cap biotech stocks struggled during the week ending March 18, 2016. The large-cap stocks within the iShares Nasdaq Biotechnology ETF (IBB) suffered the most, falling 3.9% during the week.
Alexion Pushes Down IBB’s Performance
Alexion Pharmaceuticals (ALXN) was the biggest loser among IBB’s large-cap stocks.
Biotech Stocks Begin March on a Positive Note: XLV Gained 2.1%
On March 1, crude oil inched toward $35 per barrel. The biotech stocks also moved up along with the markets.
What’s Vertex’s Strategy to Sustain the Cystic Fibrosis Market?
Vertex Pharmaceuticals (VRTX) plans to continue to create high-value drugs for CF (cystic fibrosis). In 2015, CF product revenue stood at $983 million, a 110% increase in revenue.
Vertex Will Focus on Cystic Fibrosis Market in 2016
In July 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received FDA approval for cystic fibrosis. In November 2015, it received approval from the European Commission to treat CF.
Vertex’s Cystic Fibrosis Drugs and Their Controversial Prices
Vertex Pharmaceuticals priced Kalydeco at $294,000 per year and recently increased the price to $311,000. Vertex is not the only company pricing its drugs at the higher end.
Will Vertex Pharmaceuticals’ Valuation Multiple Improve?
These valuation multiples are susceptible to company- or industry-related material news. So any positive news results in a jump in the valuation multiple.
Orkambi: Recent Addition to the Vertex Portfolio
In July 2015, Vertex Pharmaceuticals’ (VRTX) Orkambi received FDA approval for treating cystic fibrosis in the United States for patients 12 years and older with two copies of the F508del mutation.
What Are BioMarin’s Products for Treating Phenylketonuria?
Kuvan, with the active ingredient sapropterin dihydrochloride, is effective in reducing blood phenylalanine levels in PKU (or phenylketonuria) patients.
BioMarin’s Firdapse for Lambert-Eaton Myasthenic Syndrome
Firdapse is indicated for Lambert-Eaton Myasthenic syndrome. The chemical name of Firdapse is amifampridine phosphate and its active ingredient is 3,4-DAP.
What Are Wall Street’s Estimates for Vertex Pharmaceuticals?
According to Wall Street analysts’ estimates, sales for Vertex Pharmaceuticals should be $408.8 million and $472.4 million for 4Q15 and 1Q16, respectively.
Naglazyme: One of the Costliest Drugs in the United States
The wholesale cost per patient for Naglazyme is around $485,747 per year. The drug has been effective in improving walking and stair-climbing capacity.
FDA Committee Raises Concerns about Kyndrisa’s Efficacy, Safety
On November 24, 2015, the Peripheral and Central Nervous System Drugs Advisory Committee of the FDA discussed clinical data submitted by BioMarin to support Kyndrisa’s (drisapersen) NDA.
FDA Sets December 27, 2015, as Kyndrisa’s PDUFA Date
The FDA has set December 27, 2015, as the PDUFA date for BioMarin Pharmaceutical’s (BMRN) Kyndrisa (drisapersen) for Duchenne Muscular Dystrophy (or DMD) Amenable to Exon 51 Skipping.
Kanuma: An Innovative Enzyme Replacement Therapy for LAL-D
Alexion Pharmaceuticals’ Kanuma is an innovative enzyme replacement therapy for patients suffering with lysosomal acid lipase deficiency (or LAL-D).
AbbVie Topped XBI’s Large-Cap Space
AbbVie (ABBV) rose 6.5% on November 2, 2015. The stock has continued its strong run and has now gained for seven consecutive trading sessions.
Alexion Drove IBB’s Top Ten Performance
Alexion Pharmaceuticals (ALXN) rose by 5.5% and closed at $161.07. ALXN broke its four-day losing streak and moved into the green.
Key Risks that Alexion Pharmaceuticals Faces
Alexion Pharmaceuticals (ALXN) depends on a single drug Soliris for most of its revenues, which is a key risk for the company.
Alexion Acquires Synageva BioPharma
In June 2015, Alexion (ALXN) acquired Synageva BioPharma for $8.4 billion, creating a robust pipeline in the biotechnology industry.
Key Risks Vertex Pharmaceuticals Faces
Biotechnology companies such as Regeneron, Alexion, Vertex, and Biogen have excessive business concentration risk, since they earn the majority of their revenues from a small number of drugs.
Alexion Pharmaceuticals’ Cost Structure and EBITDA Margins
Mature biotechnology companies generally earn EBITDA margins of about 30% to 40%.
Illumina: Investor’s Overview of a Leading Biotechnology Company
An overview of Illumina, a leading biotechnology company, which holds a market capitalization of $27.5 billion.
Vertex Pharmaceuticals’ Cost Structure and EBITDA Margins
While mature biotechnology companies with drugs in multiple disease segments earn an average of 30%–40% EBITDA, margins of companies targeting only rare diseases can vary due to unique business models.
Alexion Pharmaceuticals Diversifies Its Research Pipeline
Alexion Pharmaceuticals (ALXN) has strengthened its drug pipeline by diversifying its research programs across the metabolic disorder segment.